TARO PHARMS FDA Approval ANDA 213269

ANDA 213269

TARO PHARMS

FDA Drug Application

Application #213269

Application Sponsors

ANDA 213269TARO PHARMS

Marketing Status

Prescription001

Application Products

001SUSPENSION;TOPICAL0.064%;0.005%0CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATEBETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

FDA Submissions

UNKNOWN; ORIG1AP2020-09-02STANDARD

Submissions Property Types

ORIG1Null7

TE Codes

001PrescriptionAB

CDER Filings

TARO PHARMS
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 213269
            [companyName] => TARO PHARMS
            [docInserts] => ["",""]
            [products] => [{"drugName":"CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE","activeIngredients":"BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE","strength":"0.064%;0.005%","dosageForm":"SUSPENSION;TOPICAL","marketingStatus":"Prescription","te":"","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"09\/02\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[]","notes":"> Label is not available on this site."}]
            [supplements] => 
            [actionDate] => 2020-09-02
        )

)

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.